Equillium, Inc. (EQ)

In August 2025, Equillium announced a securities purchase agreement for up to $50 million in gross proceeds. In November 2025, the company reported its Q3 2025 financial results, with an EPS of -$0.06. In February 2026, Equillium announced inducement awards consisting of nonstatutory stock options to new employees. As of February 2, 2026, the stock price was $1.51 per share, representing a significant increase of 127.07% over the previous year.

Equillium, Inc. does not exhibit traditional demand seasonality as its revenue streams are contingent on successful clinical trials and regulatory approvals rather than seasonal consumer demand.

Equillium, Inc. is a clinical-stage biotechnology company focused on developing novel therapeutics for severe autoimmune and inflammatory disorders. The company's lead therapeutic candidate is EQ504, a potent and selective aryl hydrocarbon receptor (AhR) modulator, planned to enter a Phase 1 clinical study in mid-2026. Another key candidate is EQ302, an orally delivered, selective bi-specific cytokine inhibitor targeting IL-15 and IL-21, currently in preclinical development. The itolizumab program is being wound down, while EQ101 is under FDA review for alopecia areata.

Equillium, Inc. is headquartered in La Jolla, California, United States, with a primary focus on developing therapeutics for unmet medical needs in the U.S.

Equillium's brand reputation is primarily influenced by its scientific advancements, clinical trial outcomes, and financial stability. Analyst ratings indicate a consensus rating of "Hold" or "Buy". The company's stock has been upgraded from a "Buy Candidate" to a "Strong Buy Candidate" by StockInvest.us. Events influencing its reputation include the positive interim analysis from the Phase 3 EQUATOR study, the significant private placement financing, and the Q3 2025 earnings beat.

Equillium, Inc. has significant institutional ownership, with 50.91% of its shares held by institutions. Major institutional owners include ADAR1 Capital Management, LLC, Janus Henderson Investors US LLC, and Adage Capital Partners Gp, L.l.c. Key individual owners include Bruce Steel and Daniel Bradbury.